VANCOUVER, British Columbia, Aug. 23, 2024 (GLOBE NEWSWIRE) — bioLytical Laboratories Inc. (the “Company” or “bioLytical”) announces that it has taken up and paid for 18,234,667 common shares (the “Purchased Shares”) at a price of CAD$0.15 per share under bioLytical’s substantial issuer bid (the “Offer”) for a total cost of CAD$2,735,200.05. The Purchased Shares represent approximately 6.20% of the common shares outstanding immediately prior to the purchase. After giving effect to the purchase, bioLytical has 275,702,595 common shares issued and outstanding.